Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Anke Hallmen"'
Autor:
Anke Hallmen, Angelika Scheuerle, Gauthier Bouche, Birgit Schmelzle, Carl Schmidt, Benjamin Mayer, Katharina Zeiler, Regine Mayer-Steinacker, Richard E. Kast, Mike-Andrew Westhoff, Lars Bullinger, Patricia Panther, Oliver Zolk, Ludwig Maier, Georg Karpel-Massler, Ziad Elshaer, Marc-Eric Halatsch, Annika Dwucet, Kristine Beckers, Tim Heiland, Bernd Schmitz, Markus D. Siegelin
Publikováno v:
Neuro-oncology Advances
Background The dismal prognosis of glioblastoma (GBM) may be related to the ability of GBM cells to develop mechanisms of treatment resistance. We designed a protocol called Coordinated Undermining of Survival Paths combining 9 repurposed non-oncolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3b9b1ea9dcb850a01dc4e3c68ffbcb8
https://pubmed.ncbi.nlm.nih.gov/34377985
https://pubmed.ncbi.nlm.nih.gov/34377985
Autor:
Marc-Eric Halatsch, Bernd Schmitz, Lars Bullinger, Oliver Zolk, Annika Dwucet, Katharina Zeiler, Birgit Schmelzle, Markus D. Siegelin, Regine Mayer-Steinacker, Ludwig Maier, Gauthier Bouche, Mike-Andrew Westhoff, Patricia Panther, Anke Hallmen, Angelika Scheuerle, Richard E. Kast, Ziad Elshaer, Kristine Beckers, Tim Heiland, Benjamin Mayer, Carl Schmidt, Georg Karpel-Massler
Purpose: The dismal prognosis of glioblastoma (GBM) may be related to the ability of GBM cells to develop mechanisms of treatment resistance. We designed a protocol called Coordinated Undermining of Survival Paths combining 9 repurposed non-oncologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1842d22c73b044a1551d481a13ae9a7
https://doi.org/10.21203/rs.3.rs-162394/v1
https://doi.org/10.21203/rs.3.rs-162394/v1
Autor:
Georg Karpel-Massler, Benjamin Mayer, Anke Hallmen, Patricia Panther, Katharina Zeiler, Tim Heiland, Ziad Elshaer, Carl Schmidt, Markus D. Siegelin, Birgit Schmelzle, Regine Mayer-Steinacker, Lars Bullinger, Oliver Zolk, Annika Dwucet, Gauthier Bouche, Bernd Schmitz, Kristine Beckers, Ludwig Maier, Angelika Scheuerle, Marc-Eric Halatsch, Mike-Andrew Westhoff, Richard E. Kast
Publikováno v:
Neuro-Oncology. 23:vi59-vi59
CUSP9v3 is a new treatment regimen for glioblastoma. It consists of continuous daily use of 9 drugs repurposed from general medicine. Their primary non-oncology uses are given in parentheses: aprepitant (nausea), auranofin (rheumatoid arthritis), cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::676e4a52d26a432aa874febb49fb3739
https://doi.org/10.1093/neuonc/noab196.229
https://doi.org/10.1093/neuonc/noab196.229